NN8555
:Inflammation
:Phase 1
Novo Nordisk is developing NN8555, a monoclonal antibody, for the treatment of patients with rheumatoid arthritis.
- Company announcements
- No company announcements matching the search criteria
- Press releases
- Novo Nordisk and Innate Pharma swap product rights (06 Oct 2008)
- Read more press releases
- Scientific abstracts
No scientific abstracts matching the search criteria
